Eyegate
Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on
the development and commercialization of therapeutics and drug delivery systems
for the treatment of diseases of the eye. Through its exclusive EyeGate® II
Delivery System, Eyegate Pharma is currently developing its first and only drug
candidate, EGP-437, which incorporates a reformulated topically active
corticosteroid that is delivered directly into the ocular tissues of patients
for the treatment of a variety of infections and diseases.
The company’s
proprietary drug delivery system is designed to address two major issues in
ophthalmic medicine, which include lack of patient compliance and safety.
Featuring a compact, elegant and easy-to-use device, the EyeGate® II Delivery System
is designed to deliver drugs non-invasively through the use of iontophoresis.
The company’s specialized delivery system has been shown to accelerate the
onset of action, dramatically reduce treatment frequency and sustain the
therapeutic effects of treatments. The easy-to-use device has already been
utilized to effectively administer more than 1,700 experimental treatments,
including more than 1,000 treatments of the company’s EGP-437. With worldwide
commercialization rights in hand, the company is aiming to fill a growing unmet
medical need and provide physicians with a responsible solution to the
treatment of increasingly common ophthalmic diseases.
The company’s
leading candidate, EGP-437, is currently in Phase III trials for the treatment
of anterior uveitis, which is a debilitating form of inflammation involving the
middle layer of the eye. The initial data from the drug candidate’s trials
revealed it as similarly effective to the currently available standard of care.
The company expects the trials to be completed by the first half of 2016. In
addition, Eyegate Pharma intends to expand the use of EGP-437 to other
inflammatory eye conditions, such as dry eye and cataract surgery. Among other
advantages, the company believes that patients may benefit from the potential
elimination of demanding dosing schedules, rapid relief of symptoms, increased
comfort and reduced side effects through the use of its drug candidate in
combination with its specialized delivery system.
With the market for
uveitis currently being dominated by branded and generic prednisolone eye drops
that are ineffective in 50%-60% of patients, the potential for a new drug
option in the sector is promising. With the company’s IPO of 1.4 million shares
of common stock, Eyegate Pharma looks to raise capital while continuing towards
the future commercialization of its leading drug candidate and non-invasive
drug delivery system.
For more
information, visit www.eyegatepharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment